Freenome on Tuesday announced the launch of its new Sanderson Study, which will use its multiomics platform, in combination with real-world data, some derived from Oracle Cerner’s Learning Health Network, to improve detection and treatment of several cancers.
WHY IT MATTERSSan Francisco-based…
Source: Healthcareitnews.com and Read More
Wall Street’s Leaders and Laggards of 2024
2024 was a mixed year for biopharma stocks, with the iShares Biotechnology ETF and SPDR S&P Biotech ETF experiencing small decreases. Federal Reserve decisions caused